Combining clinical features and MEST-C score in IgA nephropathy may be a better determinant of kidney survival

1. LI L-S, LIU Z-H, Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004; 66(3): p. 920–923.10.1111/j.1523-1755.2004.00837.x15327382Search in Google Scholar

2. REICH HN, TROYANOV S, SCHOLEY JW, CATTRAN DC, Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12): p. 3177–3183.10.1681/ASN.200705052617978307Search in Google Scholar

3. BARBOUR SJ, REICH HN, Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012; 59(6): p. 865–873.10.1053/j.ajkd.2012.02.32622497792Search in Google Scholar

4. BARBOUR S, REICH H, An update on predicting renal progression in IgA nephropathy. Curr Opin Nephrol Hypertens. 2018; 27(3): p. 214–220.10.1097/MNH.000000000000040529432215Search in Google Scholar

5. CATTRAN DC, COPPO R, COOK HT, FEEHALLY J, ROBERTS IS, TROYANOV S, et al., The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76(5): p. 534–545.Search in Google Scholar

6. TRIMARCHI H, BARRATT J, CATTRAN D, COOK H, COPPO R, HAAS M, et al., IgAN Classification Working Group of the International IgA Nephropathy Network and the Renal Pathology Society; Kidney Int. 2016;91:1014–1021Search in Google Scholar

7. CATTRAN D, COPPO R, COOK H, FEEHALLY J, ROBERTS I, TROYANOV S, et al., Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy: Rationale, clinicopathological correlations, and classification. Kidney Int. 2009; 76: p. 534–545.Search in Google Scholar

8. SOARES MF, An update on pathology of IgA nephropathy. J Bras Nephrol.2016; 38(4): p. 435–440.10.5935/0101-2800.2016006928001190Search in Google Scholar

9. BELLUR SS, LEPEYTRE F, VOROBYEVA O, TROYANOV S, COOK HT, ROBERTS IS, et al., Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy. Kidney Int. 2017; 91(1): p. 235–243.10.1016/j.kint.2016.09.02927914703Search in Google Scholar

10. TRIMARCHI H, BARRATT J, CATTRAN DC, COOK HT, COPPO R, HAAS M, et al., Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017; 91(5): p. 1014–1021.10.1016/j.kint.2017.02.00328341274Search in Google Scholar

11. HAAS M, VERHAVE JC, LIU Z-H, ALPERS CE, BARRATT J, BECKER JU, et al., A multicenter study of the predictive value of crescents in IgA nephropathy. J Am Soc Nephrol. 2017; 28(2): p. 691–701.10.1681/ASN.2016040433528002727612994Search in Google Scholar

12. RADHAKRISHNAN J, CATTRAN DC, The KDIGO practice guideline on glomerulonephritis: reading between the (guide) lines—application to the individual patient. Kidney Int. 2012; 82(8): p. 840–856.10.1038/ki.2012.28022895519Search in Google Scholar

13. CATTRAN DC, FEEHALLY J, COOK HT, LIU ZH, FERVENZA FC, MEZZANO SA, et al., Kidney disease: improving global outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012; 2(2): p. 139–274.Search in Google Scholar

14. KOBAYASHI Y, HIKI Y, FUJII K, KUROKAWA A, TATENO S, Moderately proteinuric IgA nephropathy: prognostic prediction of individual clinical courses and steroid therapy in progressive cases. Nephron. 1989; 53(3): p. 250–256.10.1159/0001857532797345Search in Google Scholar

15. TSUNODA R, USUI J, HOSHINO J, FUJII T, SUZUKI S, TAKAICHI K, et al., Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study. BMC Nephrol. 2018; 19(1): p. 222.10.1186/s12882-018-1019-x612790830189860Search in Google Scholar

16. COPPO R, TROYANOV S, BELLUR S, CATTRAN D, COOK HT, FEEHALLY J, et al., Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014; 86(4): p. 828–836.10.1038/ki.2014.63418402824694989Search in Google Scholar

17. ALAMARTINE E, SAURON C, LAURENT B, SURY A, SEFFERT A, MARIAT C, The use of the Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol, 2011; 6:2384–238810.2215/CJN.01170211335955721885791Search in Google Scholar

18. KATAFUCHI R, NINOMIYA T, NAGATA M, MITSUIKI K, HIRAKATA H, Validation study of Oxford classification of IgA nephropathy: the significance of extracapillary proliferation. Clin J Am Soc Nephrol. 2011; 6(12): p. 2806–2813.10.2215/CJN.02890311325537722157710Search in Google Scholar

19. LV J, SHI S, XU D, ZHANG H, TROYANOV S, CATTRAN DC, et al., Evaluation of the Oxford Classification of IgA nephropathy: a systematic review and meta-analysis. Am J Kidney Dis. 2013; 62(5): p. 891–899.10.1053/j.ajkd.2013.04.02123820066Search in Google Scholar

20. STANGOU M, PAPASOTIRIOU M, XYDAKIS D, OIKONOMAKI T, MARINAKI S, ZERBALA S, et al., IgA nephropathy in Greece: data from the registry of the Hellenic Society of Nephrology. Clin Kidney J. 2017; 11(1): p. 38–45.10.1093/ckj/sfx076579815729423199Search in Google Scholar

21. MAIXNEROVA D, REILY C, BIAN Q, NEPRASOVA M, NOVAK J, TESAR V, Markers for the progression of IgA nephropathy. J Nephrol. 2016; 29(4): p. 535–541.10.1007/s40620-016-0299-0554842627142988Search in Google Scholar

22. ABE K, MIYAZAKI M, KOJI T, FURUSU A, SHIOSHITA K, TSUKASAKI S, et al., Intraglomerular synthesis of complement C3 and its activation products in IgA nephropathy. Nephron. 2001; 87(3): p. 231–239.10.1159/00004592011287758Search in Google Scholar

23. MONTINARO V, GESUALDO L, RANIERI E, MONNO R, GRANDALIANO G, SCHENA FP, Renal cortical complement C3 gene expression in IgA nephropathy. J Am Soc Nephrol. 1997; 8(3): p. 415–425.10.1681/ASN.V834159071710Search in Google Scholar

24. POZZI C, Treatment of IgA nephropathy. J Nephrol. 2016; 29(1): p. 21–25.10.1007/s40620-015-0248-326577268Search in Google Scholar

25. RAUEN T, EITNER F, FITZNER C, SOMMERER C, ZEIER M, OTTE B, et al., Intensive supportive care plus immunosuppression in IgA nephropathy. N Eng J Med. 2015; 373(23): p. 2225–2236.10.1056/NEJMoa141546326630142Search in Google Scholar

26. YOON C-Y, CHANG TI, KANG EW, LIM BJ, KIE JH, KEE YK, et al., Clinical usefulness of the Oxford classification in determining immunosuppressive treatment in IgA nephropathy. Ann Med. 2017; 49(3): p. 217–229.10.1080/07853890.2016.125205827764976Search in Google Scholar

27. RUAN Y, CHEN W, LI Z, TANG X, LI J, YU X, et al., Role of immunosuppressive therapy and predictors of therapeutic effectiveness and renal outcome in IgA nephropathy with proteinuria. Arch Med Sci. 2015; 11: 332.10.5114/aoms.2015.50965442425025995749Search in Google Scholar

28. CHOI S, LEE D, JEONG K, MOON J, LEE S, LEE T, et al., Prognostic relevance of clinical and histological features in IgA nephropathy treated with steroid and angiotensin receptor blockers. Clin Nephrol. 2009; 72(5): p. 353–359.10.5414/CNP72353Search in Google Scholar

29. BARTOSIK LP, LAJOIE G, SUGAR L, CATTRAN DC, Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001; 38(4): p. 728–735.10.1053/ajkd.2001.2768911576875Search in Google Scholar

30. INKER LA, MONDAL H, GREENE T, MASASCHI T, LOCATELLI F, SCHENA FP, et al., Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016; 68(3): p. 392–401.10.1053/j.ajkd.2016.02.04227032886Search in Google Scholar